{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T17:02:59Z","timestamp":1773680579784,"version":"3.50.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.nut.2025.112861","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T19:24:18Z","timestamp":1748978658000},"page":"112861","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Insufficient diet management and monitoring of patients during phase 2 and 3 pharmaceutical clinical trials: A narrative review with a systematic approach"],"prefix":"10.1016","volume":"139","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6205-283X","authenticated-orcid":false,"given":"Nicole Y.","family":"McWhorter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1115-1405","authenticated-orcid":false,"given":"Tracy B.","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara M.","family":"Sarasua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3672-3492","authenticated-orcid":false,"given":"Christopher L.","family":"Farrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie B.","family":"Gillingham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nut.2025.112861_bib0001","series-title":"Handbook of Clinical Neurology","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/B978-0-444-64029-1.00022-9","volume":"162","author":"Ferreira","year":"2019"},{"key":"10.1016\/j.nut.2025.112861_bib0002","doi-asserted-by":"crossref","unstructured":"Bernstein LE, Rohr F, Helm JR, editors. Nutrition management of inherited metabolic diseases: lessons from Metabolic University. Cham: Springer International Publishing; 2015 [cited 2023 Oct 30]. Available from: https:\/\/link.springer.com\/10.1007\/978-3-319-14621-8","DOI":"10.1007\/978-3-319-14621-8"},{"key":"10.1016\/j.nut.2025.112861_bib0003","series-title":"Vademecum metabolicum","first-page":"174","author":"Zschocke","year":"2011"},{"issue":"7","key":"10.1016\/j.nut.2025.112861_bib0004","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s40273-014-0243-x","article-title":"The epidemiology of obesity: a big picture","volume":"33","author":"Hruby","year":"2015","journal-title":"Pharmacoeconomics"},{"issue":"10031","key":"10.1016\/j.nut.2025.112861_bib0005","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1016\/S0140-6736(16)00271-3","article-title":"Management of obesity","volume":"387","author":"Bray","year":"2016","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1016\/j.nut.2025.112861_bib0006","first-page":"S17","article-title":"Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2022 Diabetes","volume":"45","year":"2022","journal-title":"Care"},{"key":"10.1016\/j.nut.2025.112861_bib0007","unstructured":"FDA. Inborn errors of metabolism that use dietary management: considerations for optimizing and standardizing diet in clinical trials for drug product development. FDA; [cited 2023 Sep 12]. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/inborn-errors-metabolism-use-dietary-management-considerations-optimizing-and-standardizing-diet."},{"key":"10.1016\/j.nut.2025.112861_bib0008","series-title":"Principles of nutritional assessment","year":"2005"},{"issue":"10403","key":"10.1016\/j.nut.2025.112861_bib0014","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","article-title":"Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Knop","year":"2023","journal-title":"The Lancet"},{"issue":"10278","key":"10.1016\/j.nut.2025.112861_bib0015","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"The Lancet"},{"issue":"2","key":"10.1016\/j.nut.2025.112861_bib0024","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.fertnstert.2022.04.027","article-title":"Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study","volume":"118","author":"Elkind-Hirsch","year":"2022","journal-title":"Fertility Sterility"},{"issue":"11","key":"10.1016\/j.nut.2025.112861_bib0025","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ijo.2013.120","article-title":"Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study","volume":"37","author":"Wadden","year":"2013","journal-title":"Int J Obes"},{"issue":"9741","key":"10.1016\/j.nut.2025.112861_bib0026","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(10)60888-4","article-title":"Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"376","author":"Greenway","year":"2010","journal-title":"The Lancet"},{"key":"10.1016\/j.nut.2025.112861_bib0017","doi-asserted-by":"crossref","unstructured":"Roden M, Weng J, Eilbracht J, Delafont B, Kim G, Woerle HJ, et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2013;1(3):208\u201319.","DOI":"10.1016\/S2213-8587(13)70084-6"},{"issue":"10400","key":"10.1016\/j.nut.2025.112861_bib0027","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0140-6736(23)01302-8","article-title":"Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study","volume":"402","author":"Frias","year":"2023","journal-title":"The Lancet"},{"issue":"12","key":"10.1016\/j.nut.2025.112861_bib0028","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S2213-8587(16)30267-4","volume":"4","author":"Fr\u00edas","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1016\/j.nut.2025.112861_bib0029","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S2213-8587(14)70251-7","article-title":"Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: a randomised, double-blind, phase 3, non-inferiority study","volume":"3","author":"Inagaki","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"10.1016\/j.nut.2025.112861_bib0030","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(14)70120-2","article-title":"Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial","volume":"2","author":"Ridderstr\u00e5le","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"10.1016\/j.nut.2025.112861_bib0031","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1185\/03007995.2014.912983","article-title":"Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study","volume":"30","author":"Seino","year":"2014","journal-title":"Curr Med Res Opin"},{"issue":"9824","key":"10.1016\/j.nut.2025.112861_bib0032","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0140-6736(11)61879-5","article-title":"TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"379","author":"Burant","year":"2012","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.nut.2025.112861_bib0009","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1038\/s42255-023-00897-6","article-title":"Efficacy and safety of a synthetic biotic for treatment of phenylketonuria: a phase 2 clinical trial","volume":"5","author":"Vockley","year":"2023","journal-title":"Nat Metab"},{"issue":"1","key":"10.1016\/j.nut.2025.112861_bib0013","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ymgme.2018.03.006","article-title":"Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM)","volume":"124","author":"Thomas","year":"2018","journal-title":"Mol Genet Metab"},{"issue":"7","key":"10.1016\/j.nut.2025.112861_bib0033","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.2337\/dc15-1643","article-title":"Evaluation of efficacy and safety of the glucagon receptor antagonist LY2409021 in patients with type 2 diabetes: 12- and 24-week phase 2 studies","volume":"39","author":"Kazda","year":"2015","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.nut.2025.112861_bib0034","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S2213-8587(13)70149-9","article-title":"SYR-472, a novel once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor, in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"2","author":"Inagaki","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"10.1016\/j.nut.2025.112861_bib0016","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jpeds.2008.11.040","article-title":"Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study","volume":"154","author":"Trefz","year":"2009","journal-title":"J Pediatr"},{"key":"10.1016\/j.nut.2025.112861_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.155116","article-title":"PTC923 (sepiapterin) lowers elevated blood phenylalanine in subjects with phenylketonuria: a phase 2 randomized, multi-center, three-period crossover, open-label, active controlled, all-comers study","volume":"128","author":"Bratkovic","year":"2022","journal-title":"Metabolism"},{"issue":"9586","key":"10.1016\/j.nut.2025.112861_bib0019","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0140-6736(07)61234-3","article-title":"Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study","volume":"370","author":"Levy","year":"2007","journal-title":"The Lancet"},{"key":"10.1016\/j.nut.2025.112861_bib0010","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.nut.2025.112861_bib0011","unstructured":"PRISMA [cited 2023 Oct 30]. Available from: http:\/\/www.prisma-statement.org\/PRISMAStatement\/FlowDiagram?AspxAutoDetectCookieSupport=1"},{"key":"10.1016\/j.nut.2025.112861_bib0012","unstructured":"Takats S., Stillman D., Cheslack-Postava F., Bagdonas M., Jellinek A., Najdek T., et al. Zotero [Computer software]. Corporation for Digital Scholarship; 2023. Available from: https:\/\/www.zotero.org\/ Accessed 30 October 2023."},{"key":"10.1016\/j.nut.2025.112861_bib0020","article-title":"Dietary management outcomes during SynPheny-1, a phase 2 clinical trial of a live biotherapeutic, SYNB1618, for the management of phenylketonuria [Poster presentation]","author":"McWhorter","year":"2022","journal-title":"GMDI Conference"},{"key":"10.1016\/j.nut.2025.112861_bib0021","article-title":"Guidance for Industry Developing Products for Weight Management","year":"2023","journal-title":"Retrieved October"},{"key":"10.1016\/j.nut.2025.112861_bib0022","unstructured":"U.S. Food and Drug Administration. Type 2 diabetes mellitus: Evaluating the safety of new drugs for improving glycemic control. Retrieved October 2023: https:\/\/www.fda.gov\/media\/135936\/download"},{"key":"10.1016\/j.nut.2025.112861_bib0023","unstructured":"U.S. Food and Drug Administration. Diabetes mellitus: Efficacy endpoints for clinical trials investigating antidiabetic drugs and biological products. Retrieved October 2023: https:\/\/www.fda.gov\/media\/168475\/download"}],"container-title":["Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0899900725001790?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0899900725001790?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T14:14:06Z","timestamp":1756736046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0899900725001790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":34,"alternative-id":["S0899900725001790"],"URL":"https:\/\/doi.org\/10.1016\/j.nut.2025.112861","relation":{},"ISSN":["0899-9007"],"issn-type":[{"value":"0899-9007","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Insufficient diet management and monitoring of patients during phase 2 and 3 pharmaceutical clinical trials: A narrative review with a systematic approach","name":"articletitle","label":"Article Title"},{"value":"Nutrition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nut.2025.112861","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"112861"}}